|Grant Affiliation:||Ho: Ibalizumab for HIV Prevention|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||2011-08-31|
|Study Made Public:||2013-02-08|
In vitro neutralization activity of a glycan-modified ibalizumab variant
CAVD 272 is an immunogenicity study to evaluate the in vitro neutralization activity of Glyco iMab, a glycan-modified Ibalizumab variant.
Sign in to see full information about this study and to download study data.
No integrated data is available for this study.
No non-integrated data is available for this study.